The effect of the cytochrome P450 CYP2C8 polymorphism on the disposition of (R)-ibuprofen enantiomer in healthy subjects.
about
Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individualsAre cytochrome P450 CYP2C8 and CYP2C9 polymorphisms associated with ibuprofen response in very preterm infants?In vitro metabolism of exemestane by hepatic cytochrome P450s: impact of nonsynonymous polymorphisms on formation of the active metabolite 17β-dihydroexemestaneCytochrome P450 2C8 pharmacogenetics: a review of clinical studiesPharmGKB summary: ibuprofen pathways.The impact of CYP2C8 polymorphism and grapefruit juice on the pharmacokinetics of repaglinide.The effects of human CYP2C8 genotype and fluvoxamine on the pharmacokinetics of rosiglitazone in healthy subjects.Preemptive Genotyping of CYP2C8 and CYP2C9 Allelic Variants Involved in NSAIDs Metabolism for Sickle Cell Disease Pain ManagementNo significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone.Impact of the CYP2C8 *3 polymorphism on the drug-drug interaction between gemfibrozil and pioglitazone.Analysis of the Functional Polymorphism in the Cytochrome P450 CYP2C8 Gene rs11572080 with Regard to Colorectal Cancer Risk.CYP2C8 and antimalaria drug efficacy.Pharmacogenetics of chronic pain and its treatment.Selective inhibition of aromatase by a dihydroisocoumarin from Xyris pterygoblephara.The influence of CYP2C8*3 on carbamazepine serum concentration in epileptic pediatric patients.Current clinical evidence on pioglitazone pharmacogenomics.Rosiglitazone Metabolism in Human Liver Microsomes Using a Substrate Depletion Method.Personalized therapy in pain management: where do we stand?Assessment of nonsteroidal anti-inflammatory drug-induced hepatotoxicity.Pharmacogenetics and individualized therapy in children: immunosuppressants, antidepressants, anticancer and anti-inflammatory drugs.Pain, analgesia and genetics.Pharmacogenomics of acetylsalicylic acid and other nonsteroidal anti-inflammatory agents: clinical implications.PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8.Pharmacokinetic behavior presents drug therapy challenges.Efficacy and Safety of Ibuprofen in Infants Aged Between 3 and 6 Months.Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions.How polymorphisms of the cytochrome P450 genes affect ibuprofen and diclofenac metabolism and toxicity.Working Towards an Appropriate Use of Ibuprofen in Children: An Evidence-Based Appraisal.Efficacy of piroxicam for postoperative pain after lower third molar surgery associated with CYP2C8*3 and CYP2C9.Paracetamol in Patent Ductus Arteriosus Treatment: Efficacious and Safe?Acquired resistance to the anticancer drug paclitaxel is associated with induction of cytochrome P450 2C8.Genetic polymorphisms of CYP2C8, CYP2C9 and CYP2C19 in Ecuadorian Mestizo and Spaniard populations: a comparative study.Pharmacokinetic studies of enantiomers of ibuprofen and its chiral metabolites in humans with different variants of genes coding CYP2C8 and CYP2C9 isoenzymes.Genetics of the patent ductus arteriosus (PDA) and pharmacogenetics of PDA treatment.Effect of gender and CYP2C9 and CYP2C8 polymorphisms on the pharmacokinetics of ibuprofen enantiomers.
P2860
Q28237144-3091BD21-FF42-47C2-A9E4-59DD501FC76CQ33680208-5CF76ED1-469A-4109-9F81-22796C6551C6Q33777963-A26550F5-B74E-4DE6-9068-D6098D72ACDCQ35003605-09EA272E-1DB3-40B4-805C-BF4C04ECEA17Q35164718-C381391E-462A-439F-94B9-FBE61E1D7E3EQ35827353-6AED7DE4-5F1F-4DBE-B678-DAB985871853Q35827919-56C0DE6D-ACEB-4345-91D2-9DC1F2F1E240Q35909069-2BCD97BF-95B7-4F78-B0AE-F4B24B08612EQ36536042-C10618B6-1C25-4ABF-A3B9-D97921A6BF9BQ36562502-8643888C-EBF7-4B79-9D76-17F45C2E0ABAQ36611264-3723262E-A2F4-4E05-9BFA-C41974BB0A43Q36730638-9C6EDDDA-5C7D-431F-9D6C-4077EB93F3D8Q36900075-75C87D03-CE6A-46B5-AC7F-C0D2E668702CQ36924320-E5B5B883-A634-4799-BA2E-8B58063FFF0BQ37262064-E38DA65F-6A47-490B-AC97-998DCCB2379CQ37342358-58433909-61BB-455B-A40E-42239F26EA07Q37653438-8DB7319C-8CDA-4D13-AC6A-D2C3A03E65C3Q37760955-ABF42DA4-95CD-4BCA-AF74-751C57512186Q37862739-101C89A6-483E-4E3F-8DBF-5B5A4C248D44Q37892531-D4CC2740-C7FA-47F5-9426-E9353661B21EQ37944353-589C8565-314D-4B22-919A-140F0880720CQ38084125-044480EA-A378-4104-A37A-1A41B376589CQ38130410-D6DCE304-3918-4D4F-A85C-D64DAC659035Q38155930-95FDDC84-879F-4C6D-8BC0-E1AC7487673DQ38682570-A3007986-D27E-485C-A540-7951026C901AQ38684505-76757B89-A48F-4D29-904C-3D6839222C98Q38811685-F3C35836-FC13-4F13-BBF0-B262763C15DCQ39361438-45E9764A-3B52-4686-B3DE-C2039921DA13Q40983323-79707723-AF06-42B6-A6C0-8AB405446639Q41371050-89698D3A-7C83-4E3D-AFE5-373166B98421Q42496419-54264AAD-5D98-4278-B7C1-45066334AD27Q44760870-FD150D88-38A1-4541-BF73-718A4781DBFAQ45990596-99CD468F-3DFD-463C-BB68-67ADB19AC2C2Q50420641-DFBC784E-2041-4BD3-9F0F-AC3D85F9211DQ50441616-CDD8F2A0-8080-4618-BD36-3E3C0F44E761
P2860
The effect of the cytochrome P450 CYP2C8 polymorphism on the disposition of (R)-ibuprofen enantiomer in healthy subjects.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
The effect of the cytochrome P ...... nantiomer in healthy subjects.
@ast
The effect of the cytochrome P ...... nantiomer in healthy subjects.
@en
type
label
The effect of the cytochrome P ...... nantiomer in healthy subjects.
@ast
The effect of the cytochrome P ...... nantiomer in healthy subjects.
@en
prefLabel
The effect of the cytochrome P ...... nantiomer in healthy subjects.
@ast
The effect of the cytochrome P ...... nantiomer in healthy subjects.
@en
P2093
P2860
P50
P1476
The effect of the cytochrome P ...... enantiomer in healthy subjects
@en
P2093
Carmen Martínez
Francisco J G Gamito
José M Ladero
P2860
P356
10.1111/J.1365-2125.2004.02183.X
P407
P577
2005-01-01T00:00:00Z